**10.4 Irbedomide**

Irbedomide is a cereblon modulator targeting transcription factors Ikaros, an essential regulator of common lymphoid progenitor (CLP) stem cells and Aiolos, necessary for memory B-cell and plasma cell formation [123]. In SLE patients, irbedomide seems to modulate B-cell activation and differentiation downstream of TLR7 [123]. In a phase 2 trial, 54% of the patients receiving irbedomide at the dose of 0.45 mg reached SRI-4 at week 24, compared with 35% in the placebo group (P = 0.01); this difference was not statistically significant in the other irbedomide dose regimens [124].
